Proteomics

Dataset Information

0

Prostate cancer progression: From non-malignant to bone metastasisProstate cancer progression: From non-malignant to bone metastasis

ABSTRACT: Proteome characterization of gland confined prostate tumors and non-malignant prostate tissue. Whole cell protein extracts were purified from FFPE radical prostatectomy specimens for a total of 28 tumor samples and 8 adjacent non-malignant prostate tissues. Associated ProteomeXchange identifiers: PXD003430, PXD003452, PXD003515, PXD004132, PXD003615, PXD003636. Quantitative proteomic analysis of adjacent non-malignant prostate tissue (n=8) and gland confined prostate tumors (n=28) obtained from radical prostatectomy procedures; and bone metastatic prostate tumors (n=22) obtained from patients operated to relief spinal cord compression. At the time of surgery, most metastatic patients had relapsed after androgen-deprivation therapy, while 5 were previously untreated.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Prostate Adenocarcinoma Cell

DISEASE(S): Prostate Adenocarcinoma

SUBMITTER: Diego Iglesias-Gato  

LAB HEAD: Diego Iglesias-Gato

PROVIDER: PXD009868 | Pride | 2018-08-21

REPOSITORIES: Pride

Json Xml
altmetric image

Publications

The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications.

Iglesias-Gato Diego D   Thysell Elin E   Tyanova Stefka S   Crnalic Sead S   Santos Alberto A   Lima Thiago S TS   Geiger Tamar T   Cox Jürgen J   Widmark Anders A   Bergh Anders A   Mann Matthias M   Flores-Morales Amilcar A   Wikström Pernilla P  

Clinical cancer research : an official journal of the American Association for Cancer Research 20180724 21

<b>Purpose:</b> Bone is the most predominant site of distant metastasis in prostate cancer, and patients have limited therapeutic options at this stage.<b>Experimental Design:</b> We performed a system-wide quantitative proteomic analysis of bone metastatic prostate tumors from 22 patients operated to relieve spinal cord compression. At the time of surgery, most patients had relapsed after androgen-deprivation therapy, while 5 were previously untreated. An extended cohort of prostate cancer bone  ...[more]

Similar Datasets

Proteomics The proteome of localized prostate cancer, part 1
2016-06-01 | PXD003430 | Pride
Proteomics The proteome of localized prostate cancer, part 5
2016-06-01 | PXD003615 | Pride
Proteomics The proteome of localized prostate cancer, part 2
2016-06-01 | PXD003452 | Pride
Proteomics The proteome of localized prostate cancer, part 4
2016-06-01 | PXD004132 | Pride
Proteomics The proteome of localized prostate cancer, part 6
2016-06-01 | PXD003636 | Pride
Proteomics The proteome of localized prostate cancer, part 7
2016-06-01 | PXD004159 | Pride
Proteomics The proteome of localized prostate cancer, part 3
2016-06-01 | PXD003515 | Pride
Proteomics The proteome of localized prostate cancer, part 4
2016-08-18 | MSV000080068 | MassIVE
Proteomics The proteome of localized prostate cancer, part 2
2016-08-18 | MSV000080066 | MassIVE
Proteomics The proteome of localized prostate cancer, part 6
2016-08-18 | MSV000080065 | MassIVE